A NOVEL METHOD FOR REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVHF)

Figures & data

Table 1. Patient Demographics

Category
N	24
Gender	10 women/14 men
Average age (± S.D.)	53.5 ± 12 years
Average APACHE III scoreon ICU admission	105 ± 14
Primary cause of acute renal failure	Sepsis—5 (21%) Hepatorenal syndrome—5 (21%) Transplant-related conditions—7 (29%)1^1 Other—7 (29%)2^2

¹includes heart-lung, liver and bone marrow transplant recipients with acute renal failure.

²includes trauma, empyema, rhabdomyolysis.

Figure 1. Schematic of CVVHF-citrate circuit. Abbreviations used: NS = normal saline; L = liter; KCl = potassium chloride; MgSO₄ = magnesium sulfate; CaCl₂ = calcium chloride.

Figure 2. Patient and filter evaluation at various time points designated during the study period.

Figure 3. Filter patency determined as described in Methods. CVVHF-citrate filters had significantly longer filter patency than historical saline-flush filters (p = 0.00001).